Crestor vs Repatha: What to Do When One Fails

How Rosuvastatin and Evolocumab Lower LDL

Rosuvastatin blocks HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Evolocumab binds and inactivates PCSK9, a protein that degrades LDL receptors on liver cells. Because these two targets sit at different points in the same pathway, their effects are additive.

Rosuvastatin: Mechanism and Potency

Rosuvastatin is the most potent statin on a milligram-for-milligram basis. At 40 mg daily, it reduces LDL-C by approximately 50% from baseline. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced the primary composite cardiovascular endpoint by 44% versus placebo in patients with elevated high-sensitivity CRP, with LDL falling from a median of 108 mg/dL to 55 mg/dL [1]. That result cemented high-intensity statin therapy as standard of care for primary prevention in intermediate-to-high-risk patients.

Hepatic selectivity is one of rosuvastatin's advantages over other statins. Its low lipophilicity limits muscle penetration, which reduces, though does not eliminate, the risk of myopathy compared with lipophilic statins like simvastatin [2].

Evolocumab: Mechanism and Potency

Evolocumab (Repatha) is a fully human monoclonal antibody targeting PCSK9. By blocking PCSK9, it prevents LDL receptor degradation, which increases the number of functional receptors on hepatocytes and accelerates LDL clearance from the bloodstream. In the FOURIER trial (N=27,564), adding evolocumab to optimized statin therapy lowered LDL-C by a median of 59% from a baseline median of 92 mg/dL, bringing median on-treatment LDL to 30 mg/dL [3]. The trial met its primary endpoint with a 15% relative reduction in major adverse cardiovascular events (MACE) over a median follow-up of 2.2 years (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [3].

Why the Mechanisms Matter Clinically

Because statins and PCSK9 inhibitors act on different molecular targets, upregulating one pathway does not negate the other. Statins actually increase PCSK9 expression as a compensatory response to reduced intracellular cholesterol, which is why the LDL-lowering effect of PCSK9 inhibitors is often more pronounced when a patient is already on a statin [4]. This biology directly informs clinical sequencing decisions.

Defining "Failure" for Each Drug

"Failure" means different things depending on which drug you are evaluating.

What Statin Failure Looks Like

Rosuvastatin therapy is considered to have failed when one or more of the following applies:

• LDL-C remains above the individualized goal despite at least 8 weeks of maximally tolerated dosing.
• The patient develops confirmed statin-associated muscle symptoms (SAMS), defined by ACC/AHA as muscle pain or weakness with CK elevation greater than 4 times the upper limit of normal, or intolerable symptoms without CK elevation [5].
• Transaminase elevation greater than 3 times the upper limit of normal persists on repeat testing [6].

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends that, for very high-risk patients with LDL-C persistently at or above 70 mg/dL despite maximally tolerated statin therapy, a PCSK9 inhibitor should be added [5]. The guideline states: "For patients with clinical ASCVD in whom LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe" and, if LDL-C remains uncontrolled, to add a PCSK9 inhibitor [5].

What Evolocumab Failure Looks Like

True pharmacodynamic failure of evolocumab is rare. The drug produces consistent 55 to 65% LDL reductions across most genetic backgrounds. The situations that prompt a clinical reassessment include:

• Injection-site reactions or patient refusal of continued subcutaneous injections.
• Payer non-coverage creating a cost barrier that prevents sustained use.
• Inadequate adherence to the Q2W or monthly injection schedule, which may cause LDL to rebound between doses.
• In the uncommon scenario of homozygous familial hypercholesterolemia (HoFH) with two non-functional LDL receptor alleles, PCSK9 inhibition has minimal effect because there are no functional receptors to upregulate [7].

When to Add Evolocumab Rather Than Switch

For most patients who have not reached LDL goals on rosuvastatin, the right move is to add evolocumab, not replace rosuvastatin with it.

The Combination Advantage

FOURIER enrolled patients already on statins at 93% background rate. The 59% incremental LDL reduction was measured on top of that background statin therapy [3]. Removing the statin and switching entirely to evolocumab monotherapy would likely produce a smaller absolute LDL reduction, since statins increase PCSK9 expression and thereby amplify the LDL-receptor-upregulating effect of PCSK9 inhibition [4].

A 2019 analysis published in the Journal of the American College of Cardiology (Sabatine et al.) confirmed that patients with longer exposure to very low LDL levels during FOURIER had progressively greater MACE reductions, suggesting sustained combination therapy yields compounding benefit [8].

Adding Ezetimibe First

The 2018 ACC/AHA guideline recommends an intermediate step: adding ezetimibe 10 mg before escalating to a PCSK9 inhibitor [5]. Ezetimibe reduces LDL by an additional 15 to 20% and costs roughly $15, $25/month generic. The IMPROVE-IT trial (N=18,144) showed that adding ezetimibe to simvastatin after acute coronary syndrome reduced the composite cardiovascular endpoint by an absolute 2% over 7 years (HR 0.936, P=0.016) [9]. If ezetimibe brings the patient to goal, a PCSK9 inhibitor may not be needed.

When to Skip Ezetimibe and Go Directly to Evolocumab

Direct escalation to a PCSK9 inhibitor is appropriate when:

• Baseline LDL is 100 mg/dL or higher despite maximum-dose statin, indicating ezetimibe alone is unlikely to achieve a <70 mg/dL target.
• The patient has very high-risk features: recent ACS within 12 months, established peripheral artery disease, or heterozygous familial hypercholesterolemia (HeFH) with a confirmed pathogenic variant [5].
• The prescriber has prior authorization approval in place and the patient's plan covers PCSK9 inhibitors.

When to Switch to Evolocumab Monotherapy

A complete switch from rosuvastatin to evolocumab monotherapy is appropriate in a narrower set of circumstances.

Confirmed Statin Intolerance

The most clinically clear indication for monotherapy with a PCSK9 inhibitor is confirmed, reproducible statin intolerance across at least two different statins at the lowest available dose. The GAUSS-3 trial (N=511) enrolled patients with documented statin intolerance and compared evolocumab 420 mg monthly to ezetimibe [10]. Evolocumab reduced LDL by 52.8% from baseline versus a 16.7% reduction with ezetimibe (P<0.001), with a similar muscle-symptom profile between the two groups [10]. This trial is the primary evidence base for PCSK9 inhibitor monotherapy in statin-intolerant patients.

The ACC/AHA guidance specifies that statin intolerance should be confirmed by re-challenge with the same or a different statin at the lowest available dose before declaring permanent intolerance [5]. Perceived intolerance is common; the SAMSON trial (N=60) found that 90% of symptom burden attributed to statins was actually a nocebo effect when statin and placebo were compared in a blinded crossover design [11].

Homozygous FH: A Special Case

In homozygous familial hypercholesterolemia where some residual LDL receptor function exists, evolocumab 420 mg monthly may still reduce LDL by 20 to 30%, though the response is attenuated compared with HeFH [7]. The FDA approved evolocumab for HoFH in 2015 based on the TESLA Part B trial [12]. Lomitapide or evinacumab may be needed for patients with two null LDL receptor alleles.

Side-Effect Profiles Compared

Rosuvastatin and evolocumab carry distinct adverse-effect profiles that influence the switching decision.

Rosuvastatin Safety Signals

The primary concerns with rosuvastatin are:

• Myopathy and rhabdomyolysis. Risk is dose-dependent and increases at 40 mg. The FDA added a label warning in 2011 for Asian patients, who achieve higher plasma concentrations at equivalent doses [13].
• New-onset diabetes. The JUPITER trial reported a 27% relative increase in physician-reported diabetes with rosuvastatin 20 mg (HR 1.27, 95% CI 1.05 to 1.54) [1]. The absolute risk increase was small, roughly 0.6% per year, and the cardiovascular benefit substantially outweighed this risk in the trial population.
• Drug interactions. Rosuvastatin is metabolized partly by CYP2C9. Co-administration with cyclosporine, gemfibrozil, or certain antiretrovirals requires dose capping at 10 mg [6].

Evolocumab Safety Signals

Evolocumab's safety profile from FOURIER (N=27,564, median 2.2 years) was notable for its benign character [3]. Injection-site reactions occurred in 2.1% of patients. Neurocognitive concerns raised in earlier studies were not confirmed in FOURIER; the EBBINGHAUS substudy (N=1,974) found no difference in cognitive function between evolocumab and placebo over 19 months [14]. New-onset diabetes rates, muscle enzyme elevations, and liver enzyme abnormalities did not differ significantly from placebo [3].

The main safety caveat is that long-term data beyond 5 years remain limited compared with statins, which have 30-plus years of post-market surveillance.

Practical Sequencing: A Clinical Decision Path

The following framework reflects ACC/AHA 2018 guideline logic combined with FOURIER and GAUSS-3 trial data. It is intended as a clinical reference, not a replacement for individualized patient assessment.

Step 1. Start maximally tolerated statin. For most patients, rosuvastatin 20 to 40 mg daily. Check fasting lipid panel at 6 to 8 weeks.

Step 2. Assess LDL against risk-stratified goal. Very high-risk ASCVD: target <70 mg/dL. Extreme risk (recurrent ACS, HeFH plus ASCVD): target <55 mg/dL per ESC 2019 guidance [15]. If at goal, continue and monitor annually.

Step 3. If LDL remains above goal on maximum statin, add ezetimibe 10 mg. Recheck lipids at 6 weeks. Approximately 20% of patients will reach goal with this addition.

Step 4. If LDL remains above goal on statin plus ezetimibe, or if LDL is 100 mg/dL or higher and the patient has very high-risk features, add evolocumab. Dose options: 140 mg subcutaneous Q2W or 420 mg monthly. Continue rosuvastatin unless intolerance is confirmed.

Step 5. If statin intolerance is confirmed across two statins at lowest dose, switch to evolocumab monotherapy. Consider adding ezetimibe for additive LDL lowering without statin-class toxicity.

Step 6. If LDL remains elevated on triple therapy (statin plus ezetimibe plus PCSK9 inhibitor), evaluate for HoFH. Genetic testing and referral to a lipid specialist are warranted.

Cost, Access, and Prior Authorization

Evolocumab's list price runs approximately $600 per month. Amgen's patient assistance program (Repatha SupportPlus) covers patients with household incomes below 600% of the federal poverty level and reduces out-of-pocket costs to zero for qualifying patients [16]. Commercial insurance typically requires documentation of LDL-C above a threshold (usually 70 mg/dL) despite maximally tolerated statin therapy, plus at least one failed trial of ezetimibe, before approving a PCSK9 inhibitor.

Generic rosuvastatin costs $10, $30 per month at most major pharmacy chains. For patients with adequate LDL control on rosuvastatin alone, there is no cost justification for switching to evolocumab.

A 2020 cost-effectiveness analysis in JAMA Cardiology estimated the cost per quality-adjusted life-year (QALY) for evolocumab added to statin therapy at approximately $450,000, far above the conventional $100,000-per-QALY threshold [17]. The analysis noted that price reductions of 60 to 70% from list price would bring PCSK9 inhibitors within range of conventional cost-effectiveness thresholds, and negotiated prices through pharmacy benefit managers are often substantially below list price.

Monitoring Parameters After Switching or Adding

After any change in lipid-lowering regimen, a fasting lipid panel should be repeated at 6 to 8 weeks to confirm the anticipated response [5]. For evolocumab, the expected LDL response is approximately 60% from the on-statin baseline; an LDL reduction of less than 40% should prompt a review of injection technique and adherence.

For rosuvastatin, baseline and periodic CK measurement is not routinely recommended by ACC/AHA unless the patient has risk factors for myopathy, including hypothyroidism, renal impairment, or concurrent fibrate use [5]. Liver function tests are recommended before starting a statin but do not require routine follow-up unless symptoms develop [6].

Patients switching to evolocumab monotherapy for statin intolerance should have LDL measured at 4 weeks after the first dose to confirm response, since the Q2W subcutaneous regimen achieves steady-state within two injection cycles.

Special Populations

Patients With Familial Hypercholesterolemia

HeFH patients have LDL receptor function but carry one mutated allele, leading to lifelong LDL elevations averaging 190 to 400 mg/dL. Statins remain first-line, but the 2018 ACC/AHA guideline rates adding a PCSK9 inhibitor a Class IIa recommendation when LDL remains at or above 100 mg/dL despite maximally tolerated statin and ezetimibe [5]. The FH Foundation's CASCADE FH registry (N=3,738) documented that only 40% of HeFH patients reached their LDL goal on statin monotherapy, supporting early escalation [18].

Patients With Recent Acute Coronary Syndrome

The FOURIER subgroup analysis of patients enrolled within 1 year of their most recent ACS showed a larger absolute MACE reduction compared with patients with more remote events [8]. For post-ACS patients with LDL above 70 mg/dL at 6 to 8 weeks on high-intensity statin, the ACC/AHA guideline supports adding a PCSK9 inhibitor without waiting for an ezetimibe trial in patients with sufficiently elevated baseline LDL [5].

Older Adults

A prespecified FOURIER subgroup analysis of patients age 65 and older (N=8,402) found that the relative cardiovascular benefit of evolocumab was consistent with the overall trial result [3]. Rosuvastatin dose should be reduced in patients with creatinine clearance below 30 mL/min; no dose adjustment is required for evolocumab in renal impairment [6].